Amplia Therapeutics Ltd has released a press release.
Quarterly Activities and Cashflow Reports - December 2022
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Letter to Shareholders End of Year Summary and 2023 Plans
- Appendix 4D and Financial Report Half Year ended 30 Sep 22
- Amplia Appoints Dr Christopher Burns CEO & Managing Director
- Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
- AMP886 Activity in Acute Myeloid Leukemia
Later from Amplia Therapeutics
- First Patient Recruited to Cohort 2 of Accent Trial
- Dose Escalation Approved in ACCENT Clinical Trial of AMP945
- First Patient Recruited to Cohort 3 of ACCENT Trial
- Quarterly Activities and Cashflow Reports - March 23 Qtr
- ACCENT Trial Recruitment Progress
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics